TransCode Therapeutics, Inc. (RNAZ)
1.51
-0.09
(-5.62%)
USD |
NASDAQ |
Nov 05, 16:00
TransCode Therapeutics Enterprise Value : 159.85M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 159.85M |
| November 04, 2026 | 159.94M |
| November 03, 2026 | 159.91M |
| November 02, 2026 | 159.97M |
| October 30, 2026 | 159.97M |
| October 29, 2026 | 160.07M |
| October 28, 2026 | 160.08M |
| October 27, 2026 | 160.01M |
| October 26, 2026 | 160.05M |
| October 23, 2026 | 160.11M |
| October 22, 2026 | 160.06M |
| October 21, 2026 | 160.00M |
| October 20, 2026 | 160.02M |
| October 19, 2026 | 160.04M |
| October 16, 2026 | 160.04M |
| October 15, 2026 | 160.14M |
| October 14, 2026 | 160.07M |
| October 13, 2026 | 160.02M |
| October 12, 2026 | 159.97M |
| October 09, 2026 | 160.20M |
| October 08, 2026 | 160.05M |
| October 07, 2026 | 160.10M |
| October 06, 2026 | 160.12M |
| October 05, 2026 | 160.10M |
| October 02, 2026 | 159.91M |
| Date | Value |
|---|---|
| October 01, 2026 | 159.89M |
| September 30, 2026 | 160.02M |
| September 29, 2026 | 159.97M |
| September 28, 2026 | 160.05M |
| September 25, 2026 | 160.03M |
| September 24, 2026 | 159.99M |
| September 23, 2026 | 160.02M |
| September 22, 2026 | 160.11M |
| September 21, 2026 | 160.10M |
| September 18, 2026 | 159.99M |
| September 17, 2026 | 160.06M |
| September 16, 2026 | 160.02M |
| September 15, 2026 | 159.94M |
| September 14, 2026 | 159.99M |
| September 11, 2026 | 160.03M |
| September 10, 2026 | 160.03M |
| September 09, 2026 | 160.12M |
| September 08, 2026 | 160.23M |
| September 04, 2026 | 160.41M |
| September 03, 2026 | 160.50M |
| September 02, 2026 | 160.36M |
| September 01, 2026 | 160.41M |
| August 31, 2026 | 160.45M |
| August 28, 2026 | 160.53M |
| August 27, 2026 | 160.63M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.884B |
| Oncolytics Biotech, Inc. | 52.27M |
| Sangamo Therapeutics, Inc. | 38.97M |
| Sarepta Therapeutics, Inc. | 2.113B |
| Anixa Biosciences, Inc. | 89.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.750M |
| Total Expenses (Quarterly) | 6.750M |
| EPS Diluted (Quarterly) | -7.172 |
| Earnings Yield | -3.36K% |
| Normalized Earnings Yield | -2470.46 |